Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin

FDA report: Ferumoxytol for intravenous

FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease

✍ Min Lu; Martin H. Cohen; Dwaine Rieves; Richard Pazdur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Abstract On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (Feraheme™ injection, AMAG Pharmaceuticals), an iron‐containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney dise